grant
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation
Organization ROSWELL PARK CANCER INSTITUTE CORPLocation BUFFALO, UNITED STATESPosted 1 Apr 2023Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY2026AML - Acute Myeloid LeukemiaAcute B-Lymphocytic LeukemiaAcute GVHDAcute Graft Versus Host DiseaseAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Lymphoid LeukemiaAcute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAddressAfter CareAfter-TreatmentAftercareAllogenicAntigensB Cell Antigen CD19B blood cellsB cellB cell malignancyB cell progenitor acute lymphoblastic leukemiaB cellsB lymphoid malignancyB-ALLB-Cell Acute Lymphocytic LeukemiaB-Cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-CellsB-Lymphocyte Antigen CD19B-Lymphocyte Surface Antigen B4B-LymphocytesB-cellB-cell ALLB-cell precursor acute lymphoblastic leukemiaBindingBiological MarkersBlood NeutrophilBlood Polymorphonuclear NeutrophilBlood Precursor CellBlood SampleBlood specimenCAR T cellsCAR modified T cellsCAR-TCAR-TsCD19CD19 AntigensCD19 geneCD19 moleculeCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCTXCYCLO-cellCarloxanCell BodyCell LineCell TherapyCell TransplantationCellLineCellsCessation of lifeChronic GVHDCiclofosfamidaCiclofosfamideCicloxalClafenClapheneClinicalClinical MarkersClinical TrialsClonogenic Cell AssayColony-Forming Units AssayCycloblastinCycloblastineCyclophosphamCyclophosphamideCyclophosphamidumCyclophosphanCyclophosphaneCyclophosphanumCyclostinCyclostineCytophosphanCytophosphaneCytoxanDataDeathDifferentiation Antigen CD19DiseaseDisorderEffector CellEndoxanEndoxanaEnduxanFDA approvedFosfaseronGVLGenoxalGenuxalGranulocytic LeukemiaGvHDHSC transplantationHematopoiesisHematopoietic Cellular Control MechanismsHematopoietic Progenitor CellsHematopoietic Stem Cell TransplantHematopoietic Stem Cell TransplantationHematopoietic stem cellsHomologous Wasting DiseaseHumanImmune GlobulinsImmunoglobulinsImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImpairmentInfusionInfusion proceduresKineticsKnowledgeLedoxinaLeu 12LifeLinkLogicLuciferase ImmunologicLuciferasesLymphoblastic LeukemiaLymphocytic LeukemiaLymphoid LeukemiaLytotoxicityMarrow NeutrophilMiceMice MammalsMitoxanModelingModern ManMolecular InteractionMurineMusMyelocytic LeukemiaMyelogenousMyelogenous LeukemiaMyeloidMyeloid LeukemiaMyeloid ProgenitorMyeloid Progenitor CellsMyeloid Stem CellsNeosarNeutrophilic GranulocyteNeutrophilic LeukocyteNon-Lymphoblastic LeukemiaNon-Lymphocytic LeukemiaNonlymphoblastic LeukemiaNonlymphocytic LeukemiaOnset of illnessOutcomePDX modelPatient derived xenograftPatientsPolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsPre-B-Cell LeukemiaPrecursor B Lymphoblastic LeukemiaPrecursor Cell Lymphoblastic LeukemiaPrecursor Lymphoblastic LeukemiaProcytoxProgenitor CellsPrognosisPrognostic MarkerProgression-Free SurvivalsProphylactic treatmentProphylaxisRecurrent diseaseRegulatory T-LymphocyteRelapseRelapsed DiseaseRiskRunt DiseaseSendoxanSourceStrains Cell LinesSyklofosfamidT cells for CART-Cell ActivationT-CellsT-LymphocyteT4 CellsT4 LymphocytesT8 CellsT8 LymphocytesTacrolimusTestingToxic effectToxicitiesTransplant RecipientsTransplantationTregViralWorkZytoxanactivate T cellsacute graft vs host diseaseacute graft vs. host diseaseacute granulocytic leukemiaacute lymphatic leukemiaacute lymphogenous leukemiaacute lymphomatic leukemiaacute myeloid leukemiaanti-viral immunityantileukemic activityantiviral immunitybio-markersbiologic markerbiomarkerbiomarker validationblood cell formationblood cell progenitorblood progenitorblood stem cellblood stem cell transplantationblood-forming stem cellcell based interventioncell killingcell mediated interventioncell mediated therapiescell transductioncell-based therapeuticcell-based therapycellular therapeuticcellular therapycellular transductioncellular transplantchimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellschronic graft versus host diseasechronic graft vs host diseasechronic graft vs. host diseaseclinical biomarkersclinical translationclinically translatableclinically useful biomarkerscultured cell linecytotoxicitydifferential expressiondifferentially expresseddisease onsetdisease preventiondisorder onsetdisorder preventionexperimentexperimental researchexperimental studyexperimentsgraft versus host diseasegraft versus leukemiagraft vs host diseasegraft vs leukemiagraft vs leukemia effectgraft vs leukemia responsegraft vs. host diseasegraft vs. leukemiagraft vs. leukemia effectgraft vs. leukemia responsehematopoietic cell transplantationhematopoietic cellular transplantationhematopoietic progenitorhematopoietic progenitor cell transplantationhematopoietic stem progenitor cellhemopoietic progenitorhemopoietic stem cellhigh riskimmune suppressionimmune suppressive activityimmune suppressive functionimmunogenimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimprovedimproved outcomein vivoinfusionsinnovateinnovationinnovativeleukemialeukemia relapselymphatic leukemialymphogenous leukemiamarker validationmembermortalitymyeloid granulocytic leukemiamyeloid precursormyeloid stem and progenitor cellmyelosisneutrophilnoveloverexpressoverexpressionpatient derived xenograft modelpharmacologicphase 1 trialphase I trialpost treatmentpost-transplantpost-transplant diseasepost-transplantationposttransplantposttransplantationpotential biological markerpotential biomarkerpreservationpreventprevent relapsepreventingprognostic biomarkerprognostic indicatorprospectiverecurrent leukemiaregulatory T-cellsrelapse preventionrelapse riskresponse to therapyresponse to treatmentstem cellssuccesstherapeutic biomarkertherapeutic markertherapeutic responsetherapeutic targettherapy responsethymus derived lymphocytetooltranscriptional differencestransduced cellstransplanttransplant centerstransplant patienttreatment responsetreatment responsivenesstumorvalidation studies
Description preview
PROJECT SUMMARY
Post-transplant cyclophosphamide (PTCy) has substantially reduced the risk of lethal graft-versus-host disease
(GVHD) after allogeneic hematopoietic cell transplantation (alloHCT). However, like other forms of GVHD
prophylaxis, PTCy still relies upon passive graft-versus-leukemia (GVL) to prevent disease relapse.
Progression-free…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click